All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort.
Antibiotic stewardship
Antibiotics
COVID-19
LEOSS
Procalcitonin
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
07
07
2021
accepted:
14
09
2021
pubmed:
10
10
2021
medline:
26
3
2022
entrez:
9
10
2021
Statut:
ppublish
Résumé
Reported antibiotic use in coronavirus disease 2019 (COVID-19) is far higher than the actual rate of reported bacterial co- and superinfection. A better understanding of antibiotic therapy in COVID-19 is necessary. 6457 SARS-CoV-2-infected cases, documented from March 18, 2020, until February 16, 2021, in the LEOSS cohort were analyzed. As primary endpoint, the correlation between any antibiotic treatment and all-cause mortality/progression to the next more advanced phase of disease was calculated for adult patients in the complicated phase of disease and procalcitonin (PCT) ≤ 0.5 ng/ml. The analysis took the confounders gender, age, and comorbidities into account. Three thousand, six hundred twenty-seven cases matched all inclusion criteria for analyses. For the primary endpoint, antibiotic treatment was not correlated with lower all-cause mortality or progression to the next more advanced (critical) phase (n = 996) (both p > 0.05). For the secondary endpoints, patients in the uncomplicated phase (n = 1195), regardless of PCT level, had no lower all-cause mortality and did not progress less to the next more advanced (complicated) phase when treated with antibiotics (p > 0.05). Patients in the complicated phase with PCT > 0.5 ng/ml and antibiotic treatment (n = 286) had a significantly increased all-cause mortality (p = 0.029) but no significantly different probability of progression to the critical phase (p > 0.05). In this cohort, antibiotics in SARS-CoV-2-infected patients were not associated with positive effects on all-cause mortality or disease progression. Additional studies are needed. Advice of local antibiotic stewardship- (ABS-) teams and local educational campaigns should be sought to improve rational antibiotic use in COVID-19 patients.
Identifiants
pubmed: 34625912
doi: 10.1007/s15010-021-01699-2
pii: 10.1007/s15010-021-01699-2
pmc: PMC8500268
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-436Investigateurs
Julia Lanznaster
(J)
Christoph D Spinner
(CD)
Maria Madeleine Ruethrich
(MM)
Bjoern-Erik Jensen
(BE)
Martin Hower
(M)
Jan Rupp
(J)
Christoph Roemmele
(C)
Maria Vehreschild
(M)
Christian Degenhardt
(C)
Stefan Borgmann
(S)
Frank Hanses
(F)
Kerstin Hellwig
(K)
Jürgen Vom Dahl
(JV)
Sebastian Dolff
(S)
Christiane Piepel
(C)
Jan Kielstein
(J)
Silvio Nadalin
(S)
Marc Neufang
(M)
Milena Milovanovic
(M)
Kai Wille
(K)
Katja Rothfuss
(K)
Lukas Eberwein
(L)
Wolfgang Rimili
(W)
Timm Westhoff
(T)
Maximilian Worm
(M)
Gernot Beutel
(G)
Norma Jung
(N)
Joerg Schubert
(J)
Philipp Markart
(P)
Jessica Rueddel
(J)
Ingo Voigt
(I)
Robert Bals
(R)
Claudia Raichle
(C)
Jörg Janne Vehreschild
(JJ)
Carolin E M Jakob
(CEM)
Lisa Pilgram
(L)
Melanie Stecher
(M)
Maximilian Schons
(M)
Susana M Nunes de Miranda
(SMN)
Nick Schulze
(N)
Sandra Fuhrmann
(S)
Clara Brünn
(C)
Annika Claßen
(A)
Bernd Franke
(B)
Fabian Praßer
(F)
Martin Lablans
(M)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Health. 2020;8:e1453–4.
doi: 10.1016/S2214-109X(20)30444-7
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–9.
doi: 10.1016/j.cmi.2020.07.016
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266–75.
doi: 10.1016/j.jinf.2020.05.046
Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26:808–10.
doi: 10.1016/j.cmi.2020.04.024
Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh Y, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10:394–403.
doi: 10.1111/irv.12398
Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Effective Practice and Organisation of Care Group, editor. Cochrane Database Syst Rev [Internet]. 2017 [cited 2021 Apr 11]; Available from: http://doi.wiley.com/ . https://doi.org/10.1002/14651858.CD003543.pub4
Friedrichs A, Kramme E, Weis S, Pletz M. Antibiotic Stewardship: Struktur und praktische Umsetzung. Med Klin - Intensivmed Notfallmedizin. 2021;116:81–92.
doi: 10.1007/s00063-020-00745-5
Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27:520–31.
doi: 10.1016/j.cmi.2020.12.018
Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020;98:442-442A.
doi: 10.2471/BLT.20.268573
World Health Organization. WHO COVID-19 Clinical management: living guidance. 2021.
Johns Hopkins University. COVID-19 Map - Johns Hopkins Coronavirus Resource Center [Internet]. COVID-19 Map - Johns Hopkins Coronavirus Resour. Cent. 2021 [cited 2021 May 31]. Available from: https://coronavirus.jhu.edu/map.html
Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107.
doi: 10.1186/1741-7015-9-107
Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Acute Respiratory Infections Group, editor. Cochrane Database Syst Rev [Internet]. 2017 [cited 2021 Apr 9]; Available from: http://doi.wiley.com/ . https://doi.org/10.1002/14651858.CD007498.pub3
Pepper DJ, Sun J, Rhee C, Welsh J, Powers JH, Danner RL, et al. Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults. Chest. 2019;155:1109–18.
doi: 10.1016/j.chest.2018.12.029
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190–1.
doi: 10.1016/j.cca.2020.03.004
Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020;70:538–42.
doi: 10.1093/cid/ciz545
Cleland DA, Eranki AP. Procalcitonin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 May 18]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539794/
Schilling J, Lehfeld A-S, Schumacher D, Diercke M, Buda S, Haas W, et al. Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification system. Robert Koch-Institut; 2021 [cited 2021 Aug 4]; Available from: https://edoc.rki.de/handle/176904/7783
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239.
doi: 10.1001/jama.2020.2648
Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17:e1003321.
Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021;70:355–61.
doi: 10.15585/mmwr.mm7010e4
Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11:6317.
doi: 10.1038/s41467-020-19741-6
Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020;35:1123–38.
doi: 10.1007/s10654-020-00698-1
Tuty Kuswardhani RA, Henrina J, Pranata R, Anthonius Lim M, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14:2103–9.
doi: 10.1016/j.dsx.2020.10.022
Austin SR, Wong Y-N, Uzzo RG, Beck JR, Egleston BL. Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care. 2015;53:e65-72.
doi: 10.1097/MLR.0b013e318297429c
Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” Infection. 2021;49:63–73.
doi: 10.1007/s15010-020-01499-0
Jakob CEM, Kohlmayer F, Meurers T, Vehreschild JJ, Prasser F. Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19. Sci Data. 2020;7:435.
doi: 10.1038/s41597-020-00773-y
Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94.
doi: 10.1016/j.jclinepi.2004.03.012
R Core Team. R: A language and environment for statistical computing. . [Internet]. Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054–62.
doi: 10.1016/S0140-6736(20)30566-3
Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75:1681–4.
doi: 10.1093/jac/dkaa194
Kolditz M, Ewig S. Community-Acquired Pneumonia in Adults. Dtsch Aerzteblatt Online [Internet]. 2017 [cited 2021 Apr 11]; Available from: https://www.aerzteblatt.de/ . https://doi.org/10.3238/arztebl.2017.0838
Kramme E, Dalhoff K. Nosokomiale Pneumonie – neue Leitlinien. DMW - Dtsch Med Wochenschr. 2019;144:724–8.
doi: 10.1055/a-0652-8351
Shin DH, Kang M, Song K-H, Jung J, Kim ES, Kim HB. A call for antimicrobial stewardship in patients with COVID-19: a nationwide cohort study in Korea. Clin Microbiol Infect. 2021;27:653–5.
doi: 10.1016/j.cmi.2020.10.024
Ärzteblatt DÄG Redaktion Deutsches. Vermeidung verzerrter Ergebnisse in Beobachtungsstudien [Internet]. Dtsch. Ärztebl. 2009 [cited 2021 Aug 7]. Available from: https://www.aerzteblatt.de/archiv/66222/Vermeidung-verzerrter-Ergebnisse-in-Beobachtungsstudien
Nachtigall I, Lenga P, Jóźwiak K, Thürmann P, Meier-Hellmann A, Kuhlen R, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect. 2020;26:1663–9.
doi: 10.1016/j.cmi.2020.08.011
Gahlot R, Nigam C, Kumar V, Yadav G, Anupurba S. Catheter-related bloodstream infections. Int J Crit Illn Inj Sci. 2014;4:162–7.
doi: 10.4103/2229-5151.134184
Kranz* J, Schmidt* S, Wagenlehner F, Schneidewind L. Catheter-Associated Urinary Tract Infections in Adult Patients. Dtsch Ärztebl Int. 2020;117:83–8.
Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M. Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile. Science [Internet]. American Association for the Advancement of Science; 2021 [cited 2021 Aug 4];372. Available from: https://science.sciencemag.org/content/372/6545/eabg5298
Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383:1522–34.
Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? Eurosurveillance [Internet]. 2020 [cited 2021 Apr 11];25. Available from: https://www.eurosurveillance.org/content/ . https://doi.org/10.2807/1560-7917.ES.2020.25.45.2001886
Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19—an evidence based guideline. Clin Microbiol Infect. 2021;27:61–6.
doi: 10.1016/j.cmi.2020.09.041